NCT03381508

Brief Summary

The software embedded in recent continuous positive pressure devices enables the analysis of the level of leakage that occurs during treatment around the mask or from the mouth. However, there is no clear threshold defining when it would be appropriate to implement means for correcting these leaks. In addition, the calculation methods used to detect/measure leaks and the terminology used vary according to the manufacturers of continuous pressure devices, which also complicates the clinical interpretation of the leakage reports provided by the various devices. In daily practice, when a patient complains of unintentional leakage, technicians adjust the mask, replace the nasal-mask by an oro-nasal mask or install a chinstrap. Nevertheless, those strategies are not always effective in reducing leakage or patient's complaints. A better understanding of the mechanisms beyond leak appearance for a given patient could lead to individualised leak-treatment solutions. Pressure level, mandibular behaviour, respiratory effort, sleep position or sleep stages may contribute to leak emergence. A recent exploratory study has proposed a genuine analysis method of determining factors of unintentional-leaks using polysomnographic recordings in OSA patients treated with automatic Continuous Positive Airway Pressure (auto-CPAP). Based on the same methodology, the NOMICS company (Liège, Belgium) has developed a polygraphic device (Brizzy®) recording unintentional leakage during auto-CPAP treatment and providing an etiological analysis of unintentional-leaks via a software named APIOS. Due to the innovative nature of the analysis, it appears necessary to validate it onto a population of OSA patients treated with auto-CPAP. Also, to our knowledge, there is no descriptive data of the distribution of the determinants of unintentional leaks in such a population. From this perspective, the investigators aim to retrospectively analyse some polygraphic recordings that have been performed with the Brizzy® on OSA patients treated with auto-CPAP. The primary objective of this study is to identify and describe the determinants of unintentional leaks for a population of patients with OSA and treated with an auto-CPAP device

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
79

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2018

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 18, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 22, 2017

Completed
19 days until next milestone

Study Start

First participant enrolled

January 10, 2018

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 20, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 20, 2018

Completed
Last Updated

July 2, 2020

Status Verified

June 1, 2020

Enrollment Period

3 months

First QC Date

December 18, 2017

Last Update Submit

June 30, 2020

Conditions

Keywords

CPAPmasksunintentional leakleakage

Outcome Measures

Primary Outcomes (4)

  • Mouth-opening odds ratio

    For each patient presenting with an unintentional leak, determination of odds ratios for mouth-opening.

    day 0 (transversal study)

  • Auto-CPAP pressure level odds ratio

    For each patient presenting with an unintentional leak, determination of odds ratios for Auto-CPAP pressure level

    day 0 (transversal study)

  • Sleep position odds ratio

    For each patient presenting with an unintentional leak, determination of odds ratios for sleep position

    day 0 (transversal study)

  • Respiratory effort (increase in the Jawac signal > 0.3 mm) odds ratio

    For each patient presenting with an unintentional leak, determination of odds ratios respiratory effort

    day 0 (transversal study)

Secondary Outcomes (5)

  • Epworth scale score

    day 0 (transversal study)

  • Pichot scale

    day 0 (transversal study)

  • Occurrence of nasal obstruction

    day 0 (transversal study)

  • Occurrence of mouth dryness

    day 0 (transversal study)

  • Occurrence of nasal dryness

    day 0 (transversal study)

Other Outcomes (10)

  • Type/brand of mask and device used

    day 0 (transversal study)

  • Presence of heated humidifier

    day 0 (transversal study)

  • Presence of chinstraps.

    day 0 (transversal study)

  • +7 more other outcomes

Study Arms (1)

The study population

The study population corresponds to patients with obstructive sleep apnea syndrome treated via continuous positive pressure and monitored according to usual practice with the latest Brizzy device. Intervention: Brizzy continuous positive pressure device

Device: Brizzy continuous positive pressure device

Interventions

Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.

The study population

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population corresponds to patients (all meeting eligibility criteria) with obstructive sleep apnea syndrome treated via continuous positive pressure and monitored according to usual practice with the latest Brizzy device.

You may qualify if:

  • Sleep recordings from patients with OSA treated via auto-CPAP and monitored with Brizzy® device (including measures of non-intentional leaks) between June 1st and December 31th, 2017.

You may not qualify if:

  • The patient opposes the usage of his/her data
  • Minors or adults under any kind of guardianship
  • Fixed pressure
  • Bilevel positive airway pressure devices
  • Adaptive servo-ventilation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Polyclinic Saint-Privat

Boujan-sur-Libron, 34760, France

Location

University Hospital of Grenoble

Grenoble, France

Location

Hôpital Arnaud de Villeneuve

Montpellier, France

Location

Related Publications (2)

  • Lebret M, Arnol N, Martinot JB, Lambert L, Tamisier R, Pepin JL, Borel JC. Determinants of Unintentional Leaks During CPAP Treatment in OSA. Chest. 2018 Apr;153(4):834-842. doi: 10.1016/j.chest.2017.08.017. Epub 2017 Aug 26.

  • Lebret M, Jaffuel D, Suehs CM, Mallet JP, Lambert L, Rotty MC, Pepin JL, Matzner-Lober E, Molinari N, Borel JC. Feasibility of Type 3 Polygraphy for Evaluating Leak Determinants in CPAP-Treated OSA Patients: A Step Toward Personalized Leak Management. Chest. 2020 Nov;158(5):2165-2171. doi: 10.1016/j.chest.2020.05.593. Epub 2020 Jun 13.

MeSH Terms

Conditions

Sleep Apnea, Obstructive

Condition Hierarchy (Ancestors)

Sleep Apnea SyndromesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Officials

  • Jean-Christian Borel, PhD

    University Hospital, Grenoble

    PRINCIPAL INVESTIGATOR
  • Nicolas Molinari, PhD

    University Hospital, Montpellier

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2017

First Posted

December 22, 2017

Study Start

January 10, 2018

Primary Completion

April 20, 2018

Study Completion

April 20, 2018

Last Updated

July 2, 2020

Record last verified: 2020-06

Locations